Treatment Outcomes for Adults and Adolescents in Mental Health Residential and Day Treatment
Skyland Trail is a trailblazer in the area of outcomes research, which is an integral part of our evidence-based treatment model. Our robust outcomes and research program employs evaluative instruments considered to be the gold standards in the mental health field to measure the effectiveness of our treatment programs.
Most patients have reduced symptoms as a result of treatment, and our outcomes data indicate that many patients make even more progress. They experience a clinically meaningful change – one that science has shown impacts how a patient feels and functions.
For many patients, this also means achieving remission. Based on cutoffs established in the psychiatric literature, remission means that the level of symptoms present no longer meets criteria for the diagnosis.
2023 Adult Patient Outcomes
Key Outcomes
- 78% of patients reported mild hopelessness or no hopelessness at discharge 1
- 90% of patients reported positive feelings towards taking psychiatric medication at discharge 2
- 65% of patients with severe anxiety at admission who completed the program experienced clinically significant reduction in anxiety symptoms at discharge 3
- 67% of patients who completed the program experienced mild to no depression symptoms at discharge 4
- 100% of patients with bipolar disorder who completed the program experienced remission of mania symptoms at discharge 5
Adult Patients with Depression
2023 Adolescent Patient Outcomes
Key Outcomes
- 86% of patients who completed Prolonged Exposure (PE) therapy experienced clinically significant reduction in PTSD symptoms 6
- 79% of patients who completed the program experienced mild or no depression symptoms at discharge 7
- 59% of residential patients who completed the program reported anxiety symptoms at or below the average at discharge 8
Adolescent Patients with Depression
Footnotes: 1 Beck Hopelessness Scale: Beck AT, Weissman A, Lester D, Trexler L. (1074). The measurement of pessimism: The Hopelessness Scale. Journal of Consulting and Clinical Psychology, 42(6), 861-865. 2 Medication Attitude Inventory: Hogan TP, Awad AG, & Eastwood R. (1983). A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychological Medicine, 13, 177-183. 3 Hamilton M: The assessment of anxiety states by rating. British Journal of Medical Psychology, 32:50-55,1959. 4 Montgomery, S.A. & Åsberg, M. (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382-389. 5 Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry, 133:429-435, 1978. 6 Blevins, C. A., Weathers, F. W., Davis, M. T., Witte, T. K., & Domino, J. L. (2015). The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): Development and Initial Psychometric Evaluation. Journal of traumatic stress, 28(6), 489–498. 7 Dozois, D. J. A., Dobson, K. S., & Ahnberg, J. L. (1998). A psychometric evaluation of the Beck Depression Inventory–II. Psychological Assessment, 10(2), 83–89. 8 March, J.S., Parker, J.D.A., Sullivan, K., Stallings, P., Conners, C. K. (1997). The Multidimensional Anxiety Scale for Children (MASC): Factor Structure, Reliability, and Validity. Journal of the American Academy of Child & Adolescent Psychiatry, 36(4), 554–565.
